TG
EstablishedThyroglobulin is the standard biomarker for monitoring differentiated thyroid cancer recurrence after treatment.
Thyroglobulin is the main blood test used to watch for thyroid cancer coming back after treatment. About one in four patients has an antibody that interferes with this test, requiring both tests to be checked together, and even some thyroid supplements or unrelated treatments can throw off the result.
Thyroglobulin (Tg) is a protein produced by both healthy thyroid follicles and differentiated thyroid cancer cells, serving as the standard biomarker for monitoring thyroid cancer after treatment.
After total thyroidectomy and radioactive iodine ablation, a rising or persistently detectable thyroglobulin is usually the first detectable sign of thyroid cancer recurrence, correlating with residual or recurrent disease burden.
ATA guidelines consider undetectable Tg during TSH stimulation to be <1 ng/mL and during TSH suppression to be <0.2 ng/mL for patients who have undergone total thyroidectomy and radioactive iodine ablation; a significant, well-documented interference problem exists since thyroglobulin antibodies (present in up to 25% of thyroid cancer patients) can falsely suppress thyroglobulin readings, requiring simultaneous antibody testing.
Rising thyroglobulin or thyroglobulin antibody levels should prompt additional imaging investigation and potentially additional therapy; unusual interference has even been reported from desiccated thyroid extract supplements (like Armour Thyroid) and IV immunoglobulin therapy, both of which can cause misleading Tg elevations unrelated to cancer recurrence.
Thyroglobulin antibodies (up to 25% of patients) and even certain supplements can cause significant test interference.
- PMC. (2021). Two Cases of Armour Thyroid Interference in Thyroglobulin Monitoring for Thyroid Cancer.
- ScienceDirect. (2023). One-year Thyroglobulin Levels as a Predictive Measure for Recurrence in Treated Differentiated Thyroid Cancer.